BB Biotech: Next phase of biotechnology–why innovation, M&A & stock selection matter more than ever

Hosted by Dr Arron Aatkar, director, healthcare, this webinar features Dr Christian Koch, head of BB Biotech team. Dr Koch provides an update on the company, followed by a Q&A session. BB Biotech (SIX: BION), a Swiss-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BB Biotech is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20–50 stock portfolio. Dr. Christian Koch, head of the BB Biotech team since 2025 and executive board member of Bellevue Asset Management, joined Bellevue Asset Management in 2014 as a portfolio manager at BB Biotech. From 2013–14 he was a sell-side pharma and biotech equity analyst at Bank am Bellevue in Küsnacht and from 2010–13 a research associate at the Institute of Pharmaceutical Sciences at ETH Zurich.